The National Kidney Foundation continues to honor some of the nation’s leading kidney disease researchers, clinicians, patient advocates, government officials and corporate partners at the NKF Spring Clinical Meetings.
Keryx Biopharmaceuticals has been selected as the recipient of the 2018 Corporate Innovator Award, which was established to recognize industry partners that advance nephrology by addressing an unmet medical need or by improving upon an existing practice, therapeutic or technology. According to a press release from the foundation, in November 2017, Keryx Biopharmaceuticals received expanded FDA approval of ferric citrate (Auryxia) tablets to include the treatment of iron-deficiency anemia in adult patients with chronic kidney disease who are not on dialysis, making it the only oral treatment option developed and approved specifically for these patients.
Alan S. Kliger, MD, has been selected as the recipient of the 2018 J. Michael Lazarus Distinguished Lecture, which was established to honor Lazarus for his major contributions to the clinical science and care of patients with dialysis, and to recognize individuals whose research has yielded novel insights related to renal replacement therapy. Kliger, a clinical professor of medicine at Yale University School of Medicine and vice president and medical director of clinical integration at Yale New Haven Health System, is nationally recognized for his clinical expertise in kidney function and care, and for his commitment to patient safety and to improving quality of care.
Andrew S. Narva, MD, has been selected as the recipient of the 2018 Public Service Award, which honors those who have dedicated their careers to public service and who have helped shape public policies or government programs that improve outcomes for kidney patients. Narva, the current director of the National Kidney Disease Education Program at the NIH, previously served as director of the Kidney Disease Program for the Indian Health Service. In that position, he helped institute interventions that halved the rate of diabetes-related kidney failure among tribes.